{"id":"https://openalex.org/W2106773737","doi":null,"title":"Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.","display_name":"Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.","publication_year":1988,"publication_date":"1988-09-01","ids":{"openalex":"https://openalex.org/W2106773737","mag":"2106773737","pmid":"https://pubmed.ncbi.nlm.nih.gov/2970294"},"language":"en","primary_location":{"id":"pmid:2970294","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2970294","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006396363","display_name":"James A. Stewart","orcid":"https://orcid.org/0000-0001-8920-8809","observed_orcids":["https://orcid.org/0000-0001-8920-8809"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J A Stewart","raw_affiliation_strings":["Department of Medicine, Vermont Regional Cancer Center, Burlington 05401"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Vermont Regional Cancer Center, Burlington 05401","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046856694","display_name":"John J. McCormack","orcid":"https://orcid.org/0000-0002-1086-0915","observed_orcids":["https://orcid.org/0000-0002-1086-0915"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J J McCormack","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109158956","display_name":"W P Tong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W Tong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031281996","display_name":"Jane B. Low","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J B Low","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101776165","display_name":"John D. Roberts","orcid":"https://orcid.org/0000-0003-2020-6201","observed_orcids":["https://orcid.org/0000-0003-2020-6201"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J D Roberts","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062670844","display_name":"Alton J. Blow","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Blow","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049206298","display_name":"Lloyd R. Whitfield","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L R Whitfield","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051048759","display_name":"Larry D. Haugh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L D Haugh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058300476","display_name":"William R. Grove","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W R Grove","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110185143","display_name":"A.J. Grillo-L\u00f3pez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A J Lopez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.2267,"has_fulltext":false,"cited_by_count":28,"citation_normalized_percentile":{"value":0.77785106,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"48","issue":"17","first_page":"5029","last_page":"35"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.6234999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.6234999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.1736000031232834,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.021700000390410423,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trimetrexate","display_name":"trimetrexate","score":1.0},{"id":"https://openalex.org/keywords/dihydrofolate-reductase-inhibitors","display_name":"dihydrofolate reductase inhibitors","score":0.921999990940094},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.734000027179718},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.531000018119812},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.8949999809265137},{"id":"https://openalex.org/keywords/methotrexate-resistance","display_name":"methotrexate resistance","score":0.7940000295639038},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8080000281333923},{"id":"https://openalex.org/keywords/schedule-dependency","display_name":"schedule dependency","score":0.4830000102519989},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.5979999899864197},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6470000147819519},{"id":"https://openalex.org/keywords/mucositis","display_name":"mucositis","score":0.6209999918937683},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.5849999785423279},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7101825475692749},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.6669623255729675},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6646173000335693},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6110920906066895},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.493965208530426},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4807531535625458},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.47793224453926086},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.47709283232688904},{"id":"https://openalex.org/C2781382166","wikidata":"https://www.wikidata.org/wiki/Q50573407","display_name":"Antifolate","level":4,"score":0.4464942514896393},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.43659672141075134},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.39189857244491577},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33933210372924805},{"id":"https://openalex.org/C2778397455","wikidata":"https://www.wikidata.org/wiki/Q50429865","display_name":"Antimetabolite","level":3,"score":0.13615629076957703}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001853","descriptor_name":"Bone Marrow","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004341","descriptor_name":"Drug Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009061","descriptor_name":"Mouth Mucosa","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D012867","descriptor_name":"Skin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016597","descriptor_name":"Trimetrexate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:2970294","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2970294","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Journal Article"},{"id":"mag:2106773737","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2970294","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W1525999130","https://openalex.org/W1530463449","https://openalex.org/W1551369977","https://openalex.org/W1559420331","https://openalex.org/W1998537561","https://openalex.org/W1999650907","https://openalex.org/W2003225109","https://openalex.org/W2004685064","https://openalex.org/W2140758506","https://openalex.org/W2167805334","https://openalex.org/W2400812450"],"related_works":["https://openalex.org/W2041817630","https://openalex.org/W2093217501","https://openalex.org/W1605881656","https://openalex.org/W2049345149","https://openalex.org/W1997065239","https://openalex.org/W2070291488","https://openalex.org/W2126870486","https://openalex.org/W2412178722","https://openalex.org/W2086691599","https://openalex.org/W1988328608"],"abstract_inverted_index":{"Trimetrexate":[0,151],"(TMQ;":[1],"NSC":[2],"352122)":[3],"is":[4,212],"a":[5,37,82,160,179,193],"potent":[6],"inhibitor":[7],"of":[8,44,111,172,184,228,234],"dihydrofolate":[9],"reductase":[10],"with":[11,59,126],"good":[12,53],"activity":[13,145],"against":[14,33],"murine":[15],"i.p.-implanted":[16],"B16":[17],"melanoma":[18],"and":[19,29,41,73,91,104,114,118,136,140,231],"colon":[20],"26":[21],"tumors.":[22],"Preclinical":[23],"antineoplastic":[24],"activity,":[25],"demonstrated":[26],"schedule":[27,211],"dependency,":[28],"data":[30],"suggesting":[31],"effectiveness":[32],"methotrexate-resistant":[34],"cells":[35],"prompted":[36],"Phase":[38,203],"I":[39],"clinical":[40],"pharmacokinetic":[42,79],"study":[43],"trimetrexate":[45],"using":[46,63,81,206],"an":[47],"i.v.":[48,210],"daily":[49,64],"x5":[50,94,209],"schedule.":[51],"Forty-three":[52],"performance":[54],"status":[55],"patients":[56,176,201],"were":[57,76,107,168],"treated":[58],"12":[60],"dose":[61,89,186,199],"levels":[62],"doses":[65,110],"varying":[66],"from":[67,153],"0.5":[68],"to":[69],"15":[70,92],"mg/m2/d.":[71],"Plasma":[72],"urine":[74,191],"samples":[75],"obtained":[77],"for":[78,143,200],"analysis":[80],"high-performance":[83],"liquid":[84],"chromatographic":[85],"method.":[86],"Myelosuppression":[87],"was":[88,95,146,188],"limiting":[90],"mg/m2/d":[93,214],"the":[96,170,185,207,226,235],"maximum":[97],"tolerated":[98],"dose.":[99],"White":[100],"blood":[101],"cell":[102],"(WBC)":[103],"platelet":[105,119],"toxicity":[106,132],"noted":[108],"at":[109],"1.6":[112],"mg/m2":[113],"above.":[115],"Median":[116],"WBC":[117],"nadirs":[120],"occurred":[121],"on":[122,225],"approximately":[123],"Days":[124,129],"11-12":[125],"recovery":[127],"by":[128,178],"15-18.":[130],"Nonhematological":[131],"included":[133],"mucositis,":[134],"nausea":[135],"vomiting,":[137],"stomatitis,":[138],"diarrhea,":[139],"rash.":[141],"Evidence":[142],"antitumor":[144],"seen":[147],"in":[148,169,175,190,202],"seven":[149],"patients.":[150],"elimination":[152,166],"plasma":[154],"could":[155],"be":[156,222],"represented":[157,177],"as":[158],"either":[159],"bi-":[161],"or":[162],"triexponential":[163,180],"process.":[164],"Terminal":[165],"half-lives":[167],"range":[171],"5-14":[173],"h":[174],"model.":[181],"Approximately":[182],"10-20%":[183],"administered":[187],"excreted":[189],"over":[192],"24-h":[194],"period.":[195],"The":[196],"recommended":[197],"starting":[198],"II":[204],"trials":[205],"d":[208],"8.0":[213],"repeated":[215],"every":[216],"21":[217],"days.":[218],"Dose":[219],"escalations":[220],"may":[221],"possible":[223],"depending":[224],"extent":[227],"prior":[229],"therapy":[230],"individual":[232],"tolerance":[233],"drug.":[236]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}